Taraxacum Officinale Whole

Dosage for Taraxacum Officinale Whole is highly individualized and must be determined by a qualified allergist based on the patient's sensitivity levels. There is no 'one-size-fits-all' dose.

Diagnostic Dosing

• Skin Prick Test (SPT): A single drop of the extract (typically 1:10 or 1:20 w/v) is applied to the skin, followed by a superficial puncture. A positive control (histamine) and negative control (saline) are used for comparison.
• Intradermal Testing: If the SPT is negative but the clinical history strongly suggests an allergy, 0.02 to 0.05 mL of a 1:100 to 1:1000 dilution may be injected intradermally.

Immunotherapy Dosing (SCIT)

• Build-up Phase: Treatment begins with a very low dose (e.g., 0.05 mL of a 1:100,000 dilution). Doses are increased weekly or bi-weekly by 50% to 100% until the maintenance dose is reached. This phase typically lasts 3 to 6 months.
• Maintenance Phase: Once the highest tolerated dose is reached (the maintenance dose), injections are given every 2 to 4 weeks. A common maintenance dose is 0.5 mL of a 1:100 or 1:20 w/v concentration.

Taraxacum Officinale Whole is used in pediatric populations, but extreme caution is required. Children may be more sensitive to allergens and have a higher risk of systemic reactions. Dosing protocols generally follow the adult weight/volume titration, but the starting dose may be even more conservative. The safety and efficacy of immunotherapy in children under the age of 5 have not been extensively established, and healthcare providers typically weigh the benefits against the risks of systemic reactions in very young children.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the extract is not cleared through traditional renal pathways in a way that affects toxicity. However, the patient's overall health must be stable.

Hepatic Impairment

No dosage adjustments are necessary for hepatic impairment. The metabolic breakdown of allergenic proteins is independent of liver function.

Elderly Patients

Elderly patients may have reduced physiological reserve to handle a systemic reaction or anaphylaxis. Furthermore, the presence of comorbid conditions like cardiovascular disease may make the use of epinephrine (the treatment for anaphylaxis) more dangerous. Dosing should be approached with caution, and the benefit-to-risk ratio must be carefully evaluated.

Taraxacum Officinale Whole extract is NEVER for self-administration at home during the build-up phase. It must be administered in a clinical setting equipped with emergency resuscitation equipment.

• Administration: The injection is given subcutaneously, usually in the posterior aspect of the upper arm. The site should be rotated between injections.
• Observation: Patients MUST remain in the doctor's office for at least 30 minutes after every injection to monitor for signs of a systemic reaction.
• Storage: The extract must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Freezing will denature the proteins and render the extract ineffective.

If a maintenance dose is missed, the next dose may need to be reduced depending on how much time has passed. If more than 4-6 weeks have elapsed since the last injection, the allergist will typically reduce the dose to the previous level to avoid a 're-exposure' reaction. If several months are missed, the build-up phase may need to be restarted from the beginning.

An 'overdose' in the context of allergenic extracts refers to the administration of a dose that exceeds the patient's current tolerance level. Signs include:

• Severe localized swelling (larger than 10 cm).
• Generalized hives (urticaria).
• Wheezing or difficulty breathing.
• Hypotension (low blood pressure).

In the event of an overdose or systemic reaction, epinephrine must be administered immediately, and the patient must be transported to an emergency department.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or skip appointments without medical guidance.

Most patients receiving Taraxacum Officinale Whole for diagnostic or therapeutic purposes will experience some form of localized reaction. These are generally expected and indicate that the extract is immunologically active.

• Local Redness (Erythema): Redness at the injection or prick site is very common. It usually appears within minutes and resolves within a few hours.
• Local Swelling (Wheal): A raised, itchy bump at the site. In immunotherapy, this is considered 'normal' if it is smaller than the size of a half-dollar (approx. 3 cm).
• Itching (Pruritus): Localized itching is a direct result of histamine release in the skin.
• Tenderness: The injection site may feel slightly sore or bruised for 24 hours.

• Large Local Reactions (LLR): Swelling that exceeds 5-10 cm in diameter. This may require an adjustment of the next dose and the use of oral antihistamines or cold compresses.
• Fatigue: Some patients report feeling unusually tired for a few hours following an immunotherapy injection.
• Mild Nasal Congestion: A slight 'flare' of hay fever symptoms shortly after administration.

• Generalized Urticaria: Hives appearing on parts of the body away from the injection site. This is a sign of a systemic reaction.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.
• Persistent Granuloma: A small, hard lump at the injection site that may persist for weeks due to a reaction to the extract medium.

> Warning: Stop taking Taraxacum Officinale Whole and call your doctor immediately or seek emergency care if you experience any of these symptoms of anaphylaxis.

• Difficulty Breathing: Wheezing, chest tightness, or a feeling of 'throat closing.' This indicates bronchospasm or laryngeal edema.
• Hypotension: Feeling faint, dizzy, or losing consciousness. This is a sign of circulatory collapse.
• Rapid or Weak Pulse: Tachycardia associated with a drop in blood pressure.
• Nausea and Vomiting: Systemic allergic reactions can often involve the gastrointestinal tract.
• Cyanosis: Bluish tint to the lips or fingernails, indicating a lack of oxygen.

When used correctly for immunotherapy, Taraxacum Officinale Whole is intended to have long-term positive effects (desensitization). However, some patients may develop a persistent sensitivity to other plants in the Asteraceae family due to cross-reactivity. There is no evidence that long-term use of allergenic extracts causes organ damage, cancer, or autoimmune diseases. The primary 'long-term' risk is the cumulative risk of having a systemic reaction over the 3-5 years of treatment.

According to the FDA, all allergenic extracts, including Taraxacum Officinale Whole, must carry a warning regarding the risk of severe systemic reactions.

FDA Summary Warning: This product can cause severe life-threatening systemic reactions, including anaphylaxis. It should only be administered by physicians who are exceptionally experienced in the treatment of allergic diseases and who are equipped to manage such reactions. Patients with unstable asthma are at a higher risk for severe outcomes. Epinephrine should always be available for immediate use.

Report any unusual symptoms or persistent large local reactions to your healthcare provider immediately. Documentation of these reactions is critical for adjusting your treatment plan safely.

Taraxacum Officinale Whole is a potent biological substance. It is not a standard medication but a tool to modify the immune system. Patients must be aware that the primary risk is an over-activation of the immune response. It is vital that patients are honest with their healthcare provider about their current health status, especially regarding respiratory health, before each injection.

No FDA black box warnings for Taraxacum Officinale Whole are specifically listed as a unique entity, but it falls under the General Black Box Warning for Allergenic Extracts. This warning emphasizes that allergenic extracts are not interchangeable and that the concentration must be verified before every administration. It also mandates a 30-minute observation period post-injection.

• Allergic Reactions / Anaphylaxis Risk: The most significant risk. Anaphylaxis can occur even in patients who have previously tolerated the extract well. Factors that increase this risk include exercise within 2 hours of the injection, hot showers, or acute illness.
• Asthma Stability: Patients with uncontrolled or unstable asthma should not receive immunotherapy. A significant drop in FEV1 (forced expiratory volume) before an injection is a contraindication for that day's dose.
• Beta-Blocker Use: Patients taking beta-blockers (for blood pressure or glaucoma) may be resistant to the effects of epinephrine, making a systemic reaction much harder to treat and potentially fatal.
• ACE Inhibitor Use: There is some evidence that ACE inhibitors may increase the risk or severity of systemic reactions to allergenic extracts.

• Peak Flow Monitoring: For patients with asthma, monitoring peak expiratory flow before each injection is standard practice.
• Injection Site Inspection: The healthcare provider will inspect the previous injection site for large local reactions before administering the next dose.
• Vital Signs: Blood pressure and heart rate may be monitored if the patient feels unwell.

Generally, Taraxacum Officinale Whole does not cause drowsiness. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until cleared by a physician.

Alcohol should be avoided for several hours before and after an injection. Alcohol causes vasodilation (widening of blood vessels), which can increase the rate of allergen absorption from the injection site and potentially trigger a more severe reaction.

Immunotherapy is typically discontinued after 3 to 5 years of successful maintenance. There is no 'withdrawal' syndrome, but stopping the treatment prematurely may result in the return of allergy symptoms. If treatment is stopped due to a severe systemic reaction, the physician will determine if it is safe to restart at a much lower dose.

> Important: Discuss all your medical conditions, including any history of heart disease or lung problems, with your healthcare provider before starting Taraxacum Officinale Whole.

• Beta-Adrenergic Blockers (e.g., Propranolol, Atenolol): These are considered a major contraindication for allergen immunotherapy. Beta-blockers interfere with the action of epinephrine, which is the only life-saving treatment for anaphylaxis. If a patient on beta-blockers has a severe reaction to Taraxacum Officinale Whole, the standard doses of epinephrine may fail to reverse the airway obstruction and low blood pressure.

• ACE Inhibitors (e.g., Lisinopril, Enalapril): These medications may interfere with the body's natural ability to degrade kinins, potentially worsening the severity of an allergic reaction.
• MAO Inhibitors (e.g., Phenelzine): These can potentiate the effects of epinephrine, leading to a dangerous spike in blood pressure if epinephrine is needed to treat a reaction.
• Tricyclic Antidepressants (e.g., Amitriptyline): Similar to MAOIs, these can increase the cardiovascular effects of epinephrine.

• Antihistamines (e.g., Cetirizine, Loratadine): These must be stopped several days before diagnostic skin testing because they will suppress the wheal and flare reaction, leading to a false-negative result. However, they are often continued during the immunotherapy phase to reduce the discomfort of local reactions.
• Systemic Corticosteroids: High doses of oral steroids may suppress the immune response to the extract, potentially reducing the efficacy of the diagnostic test or the immunotherapy.

• Cross-Reactive Foods: Patients allergic to Taraxacum Officinale Whole may experience Oral Allergy Syndrome (OAS) when eating certain foods. This is due to 'pollen-food syndrome.' Common cross-reactive foods include honey, sunflower seeds, chamomile tea, and other members of the Asteraceae family. Consuming these foods shortly before or after an injection may increase the total 'allergic load' and trigger a reaction.

• Echinacea and Chamomile: These plants are in the same family as Taraxacum Officinale. Using these supplements while undergoing dandelion immunotherapy may increase the risk of an allergic flare-up.
• St. John's Wort: While not directly cross-reactive, it can affect the metabolism of other medications used to manage allergy symptoms.

• Skin Tests: As mentioned, Taraxacum Officinale Whole extract is itself used for a lab test (the skin prick test). Any medication that affects skin reactivity (antihistamines, certain antidepressants, topical steroids) will interfere with the accuracy of this test.

Mechanism of Interaction Summary:

• Pharmacodynamic: Beta-blockers blocking the beta-2 receptors needed for epinephrine to work.
• Pharmacodynamic: Antihistamines blocking the H1 receptors involved in the skin test reaction.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any new prescriptions for blood pressure or heart health.

Taraxacum Officinale Whole must NEVER be used in the following circumstances:

• Severe, Uncontrolled Asthma: Patients with an FEV1 consistently below 70% of predicted value are at an unacceptably high risk of fatal bronchospasm during a systemic reaction.
• Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months. The stress of a potential systemic reaction or the administration of epinephrine could trigger another cardiac event.
• Known Hypersensitivity to Excipients: Some extracts contain phenol or high concentrations of glycerin. Patients with a known severe allergy to these preservatives must not use the product.
• Inability to Communicate: Patients who cannot report early symptoms of a reaction (e.g., very young children or those with severe cognitive impairment) may not be suitable candidates for SCIT.

• Autoimmune Diseases: There is a theoretical risk that stimulating the immune system with Taraxacum Officinale Whole could exacerbate conditions like Lupus or Rheumatoid Arthritis. This must be evaluated on a case-by-case basis.
• Malignancy: Patients undergoing active chemotherapy or with advanced cancer are generally not started on immunotherapy due to their compromised immune status.
• Pregnancy (Initiation): While maintenance immunotherapy is often continued during pregnancy, starting a new course of Taraxacum Officinale Whole is generally avoided due to the risk of anaphylaxis-induced fetal hypoxia.

Patients who are allergic to Taraxacum Officinale Whole are highly likely to be cross-sensitive to:

• Ragweed (Ambrosia)
• Chrysanthemums
• Marigolds
• Daisies
• Arnica

If a patient has had a life-threatening reaction to any of these plants, the initial dose of dandelion extract must be extremely low.

> Important: Your healthcare provider will evaluate your complete medical history, including your respiratory and cardiovascular health, before prescribing Taraxacum Officinale Whole.

FDA Pregnancy Category C. There are no adequate and well-controlled studies of Taraxacum Officinale Whole in pregnant women. The primary concern is not the extract itself, which consists of natural proteins, but the risk of a systemic reaction (anaphylaxis). If a pregnant woman experiences anaphylaxis, the resulting drop in blood pressure and oxygen levels can cause severe fetal distress, permanent brain damage, or fetal death.

• Clinical Practice: Allergists typically do not start new immunotherapy during pregnancy. However, if a patient is already on a stable maintenance dose and is tolerating it well, the treatment may be continued, often at a reduced dose to further minimize the risk of a reaction.

It is not known whether the components of Taraxacum Officinale Whole are excreted in human milk. However, because the extract consists of proteins that are likely digested in the infant's stomach, the risk to a nursing infant is considered very low. Breastfeeding is not a contraindication for receiving diagnostic skin tests or immunotherapy.

Taraxacum Officinale Whole is used in children for both diagnosis and treatment. However, the American Academy of Allergy, Asthma & Immunology (AAAAI) suggests that the benefits of immunotherapy are most clear in children older than 5 years. Younger children may find the frequent injections traumatic, and they are less able to articulate the early symptoms of a systemic reaction (e.g., 'my throat feels funny'). Pediatric dosing requires meticulous titration.

In patients over 65, the decision to use Taraxacum Officinale Whole must consider the 'whole patient.' Older adults are more likely to have underlying cardiovascular disease or be taking medications like beta-blockers. The physiological 'cost' of a systemic reaction is much higher in this population. However, for an otherwise healthy senior with debilitating allergies, immunotherapy can be highly effective.

As the extract is not a drug that requires hepatic or renal clearance for detoxification, no specific dose adjustments are needed. However, patients with end-stage renal disease (ESRD) may have altered immune responses and should be monitored closely.

Liver disease does not affect the pharmacokinetics of allergenic extracts. No dosage adjustments are required for patients with cirrhosis or other liver pathologies.

> Important: Special populations require individualized medical assessment. Always inform your allergist if you become pregnant or develop new health conditions during treatment.

Taraxacum Officinale Whole acts as an exogenous antigen. In the diagnostic phase, it cross-links IgE antibodies on the surface of mast cells. This triggers a signal transduction pathway involving tyrosine kinases (such as Syk), leading to an influx of calcium ions and the release of pre-formed mediators (histamine) and newly synthesized mediators (leukotrienes).

In the therapeutic phase (immunotherapy), the mechanism shifts toward immune deviation. The extract stimulates the production of IL-10-producing regulatory T cells. These cells suppress the Th2 response that produces IgE and instead promote the production of IgG4. IgG4 acts as a 'decoy' or 'blocking' antibody, binding to the dandelion allergens before they can reach the IgE on mast cells.

• Dose-Response: There is a clear dose-response relationship in skin testing; higher concentrations produce larger wheals. In immunotherapy, higher maintenance doses are generally associated with better long-term efficacy, provided they are tolerated.
• Onset of Action: Skin prick reactions occur within 15-20 minutes. The clinical benefits of immunotherapy typically take 6 to 12 months to become noticeable.
• Duration of Effect: A single skin test has no lasting effect. Immunotherapy provides long-term relief that can last for years after the 3-5 year treatment course is completed.

| Parameter | Value |

|---|---|

| Bioavailability | Low (Subcutaneous) |

| Protein Binding | N/A (Biological Protein) |

| Half-life | Minutes to Hours (Proteins) |

| Tmax | 15-30 minutes (Local reaction) |

| Metabolism | Proteolysis |

| Excretion | Renal (Peptides) |

Taraxacum Officinale Whole extract is a complex mixture of proteins, glycoproteins, and polysaccharides. Key allergenic components include:

• Taraxinic acid glucoside: A sesquiterpene lactone that can cause contact dermatitis.
• Luteolin-7-glucoside: A flavonoid.
• Inulin: A storage polysaccharide found in the root.
• Pollen Proteins: Various proteins with molecular weights ranging from 10 to 70 kDa.

Taraxacum Officinale Whole is classified as a Standardized Chemical Allergen [EPC] and Allergenic Extract. It is related to other Asteraceae extracts like Ragweed (Ambrosia artemisiifolia) and Mugwort (Artemisia vulgaris).